A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Richter transformation (RT) is a rare complication of chronic lymphocytic leukemia (CLL) that has dismal outcomes. Upregulation of PD-1/PD-L1 drives immunological evasion in patients with RT. We hypothesized that combining nivolumab, a PD-1 blocking antibody, with the BTK inhibitor (BTKi) ibrutinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Nitin, Senapati, Jayastu, Thakral, Beenu, Ferrajoli, Alessandra, Thompson, Philip, Burger, Jan, Basu, Sreyashi, Kadia, Tapan, Daver, Naval, Borthakur, Gautam, Konopleva, Marina, Pemmaraju, Naveen, Parry, Erin, Wu, Catherine J., Khoury, Joseph, Bueso-Ramos, Carlos, Garg, Naveen, Wang, Xuemei, Lopez, Wanda, Ayala, Ana, O’Brien, Susan, Kantarjian, Hagop, Keating, Michael, Allison, James, Sharma, Padmanee, Wierda, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189379/
https://www.ncbi.nlm.nih.gov/pubmed/36287248
http://dx.doi.org/10.1182/bloodadvances.2022008790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189379/
https://www.ncbi.nlm.nih.gov/pubmed/36287248
http://dx.doi.org/10.1182/bloodadvances.2022008790

Ejemplares similares